MENLO PARK, Calif., Oct. 12, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences,” or the “Company”), an eyecare technology company focused on developing and commercializing ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. LOS ANGELES — At the American Society of Cataract and ...
Please provide your email address to receive an email when new articles are posted on . More than half of participants experienced improvement in reading speed after one treatment with TearCare.
Assuming two procedures over a 1-year time horizon, TearCare demonstrated a cost-saving advantage over CsA, reducing per-patient costs by $903 annually. Patients receiving TearCare experienced an ...
Patients treated with a single interventional eyelid procedure enabled by TearCare® technology after receiving Restasis® for the first six months of the trial realized clinically meaningful ...
MENLO PARK, Calif., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing ...
Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window We all know that ...
MENLO PARK, Calif., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences,” or the “Company”), an eyecare technology company focused on developing and commercializing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback